Transenterix Inc. (TRXC) 4.32 $TRXC
TransEnterix, Inc. Announces Exercise of Over-Allotment Option
Business Wire - Mon May 05, 3:41PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that the underwriters of its previously announced public offering of common stock partially exercised the over-allotment option granted at the time of the public offering and have purchased 1,610,000 shares of common stock at the public offering price of $4.00 per share, less underwriting discounts and commissions.
Global Hernia Repair Devices Market 2014-2018: Increase in the adoption of tension-free repair procedures for hernias
M2 - Wed Apr 30, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lfs5k4/global_hernia) has announced the addition of the "Global Hernia Repair Devices Market 2014-2018" report to their offering. A hernia is condition in which a tissue, organ or fascia of the organ protrudes through the wall of a weak muscle area. Obesity, poor nutrition, smoking, and a weak muscle area at birth are some of the causes of hernias. There are several types of hernia such as inguinal, umbilical, hiatal, femoral, and incisional. An inguinal hernia is when part of the abdominal tissue/organ protrudes into the groin area. An umbilical hernia is found in the area of the umbilicus. A hiatal hernia is when a portion of stomach protrudes through the diaphragm. A femoral hernia is when the intestine protrudes into the canal carrying the femoral artery into the upper thigh. An incisional hernia sometimes occurs if a wound from a previous surgical procedure is not completely healed. Hernia repair devices are used in procedures such as herniorrhaphy, hernioplasty, and herniotomy to correct the above mentioned types of hernia. The analysts forecast the Global Hernia Repair Devices Market will grow at a CAGR of 6.35 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Products 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - B. Braun Melsungen AG - Cook Medical Inc. - Covidien plc - C.R. Bard Inc. - Ethicon Inc. - Biomerix Corp. - CooperSurgical Inc. - Insightra Medical Inc. - KARL STORZ GmbH & Co. KG - LifeCell Corp. - Olympus Corp. - Stryker Corp. - Synovis Life Technologies Inc. - TransEnterix Inc. - W.L. Gore &Associates Inc. For more information visit http://www.researchandmarkets.com/research/lf...bal_hernia
Why TransEnterix (TRXC) Stock Is Gaining Today
at The Street - Fri Apr 25, 1:26PM CDT
TransEnterix (TRXC) had coverage initiated with a 'buy' rating by analysts at Stifel Nicolaus
TransEnterix Schedules First Quarter 2014 Earnings Release and Conference Call for May 7, 2014
Business Wire - Wed Apr 23, 4:00PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC) announced today that it plans to release first quarter 2014 financial and operating results after the market closes on Wednesday, May 7, 2014. Todd M. Pope, Chief Executive Officer and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 4:30 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix Announces First Human Cases Using Its Advanced Energy Device
Business Wire - Wed Apr 16, 6:01AM CDT
TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced the first human cases performed using its recently launched fully flexible advanced energy device.
TransEnterix, Inc. Announces NYSE MKT Market Listing Plans and Reverse Stock Split
Business Wire - Tue Apr 01, 4:15PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has received authorization to list its common shares on the NYSE MKT. In addition, its Board of Directors has approved a 1-for-5 reverse split of its issued and outstanding shares of common stock, which became effective on March 31, 2014. Trading of the Company's common shares will reflect the reverse stock split on April 2, 2014.
TransEnterix, Inc. Files Pre-Submission Documentation with FDA Regarding its SurgiBot System
Business Wire - Mon Mar 31, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has completed a pre-submission filing with the U.S. Food and Drug Administration ("FDA"
to request additional feedback from the FDA regarding its planned 510(k) filing for the SurgiBot(TM) system, pursuant to the FDA's Pre-Submission Program.
TransEnterix, Inc. Provides Update on Investor & Analyst Event
Business Wire - Tue Mar 25, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve the experience and outcomes of minimally invasive surgery, today announced it has postponed its Investor & Analyst Event previously-scheduled for April 3, 2014 in Salt Lake City due to a scheduling conflict with senior management. The Company continues to remain on track to complete its 2014 Key Objectives as outlined in the Company's March 6, 2014 press release, including completing a pre-submission FDA filing for the SurgiBot(TM) system in the first quarter. The Company is in the process of identifying an alternative date and location for the event.
TransEnterix, Inc. Reports Operating Results for the Fourth Quarter and Full Year 2013
Business Wire - Wed Mar 05, 6:00AM CST
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve how minimally invasive surgery is performed, today announced its operating and financial results for the fourth quarter and full year 2013, as well as its 2014 key objectives.
CORRECTING and REPLACING TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 4:23PM CST
First graph, end of second sentence of release should read: ...starting at 8:00 am Eastern Time the same day. (sted ...starting at 1:00 pm Eastern Time the same day.).
TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 3:56PM CST
TransEnterix, Inc. (OTCBB: TRXC) announced today that it plans to release fourth quarter and full year 2013 financial and operating results prior to the market open on Wednesday, March 5, 2014. Todd Pope, Chief Executive Officer and Joe Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these resulting starting at 1:00 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix, Inc. to present at the RBC Capital Markets 2014 Healthcare Conference
Business Wire - Tue Feb 11, 3:32PM CST
TransEnterix, Inc. (OTCBB:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets 2014 Healthcare Conference in New York. The presentation is scheduled to take place at 2:35 pm Eastern Time on Tuesday, February 25, 2014.
TransEnterix Enters Next Phase of Development of SurgiBot(TM) System
Business Wire - Mon Jan 13, 6:00AM CST
TransEnterix, Inc. (OTCBB: TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that multiple surgeons have used SurgiBot, the company's patient-side minimally invasive robotic system, to successfully complete general surgery procedures in the porcine model. The procedures performed in the pre-clinical testing included cholecystectomy and sleeve gastrectomy.
TransEnterix, Inc. Announces Exercise of Over-Allotment Option
Business Wire - Mon May 05, 3:41PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that the underwriters of its previously announced public offering of common stock partially exercised the over-allotment option granted at the time of the public offering and have purchased 1,610,000 shares of common stock at the public offering price of $4.00 per share, less underwriting discounts and commissions.
Global Hernia Repair Devices Market 2014-2018: Increase in the adoption of tension-free repair procedures for hernias
M2 - Wed Apr 30, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lfs5k4/global_hernia) has announced the addition of the "Global Hernia Repair Devices Market 2014-2018" report to their offering. A hernia is condition in which a tissue, organ or fascia of the organ protrudes through the wall of a weak muscle area. Obesity, poor nutrition, smoking, and a weak muscle area at birth are some of the causes of hernias. There are several types of hernia such as inguinal, umbilical, hiatal, femoral, and incisional. An inguinal hernia is when part of the abdominal tissue/organ protrudes into the groin area. An umbilical hernia is found in the area of the umbilicus. A hiatal hernia is when a portion of stomach protrudes through the diaphragm. A femoral hernia is when the intestine protrudes into the canal carrying the femoral artery into the upper thigh. An incisional hernia sometimes occurs if a wound from a previous surgical procedure is not completely healed. Hernia repair devices are used in procedures such as herniorrhaphy, hernioplasty, and herniotomy to correct the above mentioned types of hernia. The analysts forecast the Global Hernia Repair Devices Market will grow at a CAGR of 6.35 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Products 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - B. Braun Melsungen AG - Cook Medical Inc. - Covidien plc - C.R. Bard Inc. - Ethicon Inc. - Biomerix Corp. - CooperSurgical Inc. - Insightra Medical Inc. - KARL STORZ GmbH & Co. KG - LifeCell Corp. - Olympus Corp. - Stryker Corp. - Synovis Life Technologies Inc. - TransEnterix Inc. - W.L. Gore &Associates Inc. For more information visit http://www.researchandmarkets.com/research/lf...bal_hernia
Why TransEnterix (TRXC) Stock Is Gaining Today
at The Street - Fri Apr 25, 1:26PM CDT
TransEnterix (TRXC) had coverage initiated with a 'buy' rating by analysts at Stifel Nicolaus
TransEnterix Schedules First Quarter 2014 Earnings Release and Conference Call for May 7, 2014
Business Wire - Wed Apr 23, 4:00PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC) announced today that it plans to release first quarter 2014 financial and operating results after the market closes on Wednesday, May 7, 2014. Todd M. Pope, Chief Executive Officer and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 4:30 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix Announces First Human Cases Using Its Advanced Energy Device
Business Wire - Wed Apr 16, 6:01AM CDT
TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced the first human cases performed using its recently launched fully flexible advanced energy device.
TransEnterix, Inc. Announces NYSE MKT Market Listing Plans and Reverse Stock Split
Business Wire - Tue Apr 01, 4:15PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has received authorization to list its common shares on the NYSE MKT. In addition, its Board of Directors has approved a 1-for-5 reverse split of its issued and outstanding shares of common stock, which became effective on March 31, 2014. Trading of the Company's common shares will reflect the reverse stock split on April 2, 2014.
TransEnterix, Inc. Files Pre-Submission Documentation with FDA Regarding its SurgiBot System
Business Wire - Mon Mar 31, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has completed a pre-submission filing with the U.S. Food and Drug Administration ("FDA"
to request additional feedback from the FDA regarding its planned 510(k) filing for the SurgiBot(TM) system, pursuant to the FDA's Pre-Submission Program. TransEnterix, Inc. Provides Update on Investor & Analyst Event
Business Wire - Tue Mar 25, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve the experience and outcomes of minimally invasive surgery, today announced it has postponed its Investor & Analyst Event previously-scheduled for April 3, 2014 in Salt Lake City due to a scheduling conflict with senior management. The Company continues to remain on track to complete its 2014 Key Objectives as outlined in the Company's March 6, 2014 press release, including completing a pre-submission FDA filing for the SurgiBot(TM) system in the first quarter. The Company is in the process of identifying an alternative date and location for the event.
TransEnterix, Inc. Reports Operating Results for the Fourth Quarter and Full Year 2013
Business Wire - Wed Mar 05, 6:00AM CST
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve how minimally invasive surgery is performed, today announced its operating and financial results for the fourth quarter and full year 2013, as well as its 2014 key objectives.
CORRECTING and REPLACING TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 4:23PM CST
First graph, end of second sentence of release should read: ...starting at 8:00 am Eastern Time the same day. (sted ...starting at 1:00 pm Eastern Time the same day.).
TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 3:56PM CST
TransEnterix, Inc. (OTCBB: TRXC) announced today that it plans to release fourth quarter and full year 2013 financial and operating results prior to the market open on Wednesday, March 5, 2014. Todd Pope, Chief Executive Officer and Joe Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these resulting starting at 1:00 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix, Inc. to present at the RBC Capital Markets 2014 Healthcare Conference
Business Wire - Tue Feb 11, 3:32PM CST
TransEnterix, Inc. (OTCBB:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets 2014 Healthcare Conference in New York. The presentation is scheduled to take place at 2:35 pm Eastern Time on Tuesday, February 25, 2014.
TransEnterix Enters Next Phase of Development of SurgiBot(TM) System
Business Wire - Mon Jan 13, 6:00AM CST
TransEnterix, Inc. (OTCBB: TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that multiple surgeons have used SurgiBot, the company's patient-side minimally invasive robotic system, to successfully complete general surgery procedures in the porcine model. The procedures performed in the pre-clinical testing included cholecystectomy and sleeve gastrectomy.
